Antje Lukas

Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation.

G. Kristiansen, D. Dietrich, A. Hartmann, 2010, The Journal of molecular diagnostics : JMD.

Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.

J. Foekens, J. Nährig, G. Kristiansen, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Performance of standardized BEAMing platform for detecting RAS mutations in the blood of metastatic colorectal cancer (mCRC) patients.

J. Macioszek, D. Edelstein, F. Jones, 2016 .

Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression.

J. Rogan, M. Braun, T. Germetaki, 2020, Future oncology.

Accuracy of plasma RAS mutation testing for therapy selection and monitoring of colorectal cancer patients

J. Albanell, B. Bellosillo, C. Montagut, 2016 .